INTRODUCTION

Pegloticase (brand name Krystexxa) is a recombinant uricase that is used for the treatment of chronic gout in adult patients refractory to conventional therapy.

This plasmid is designed for expressing Krystexxa in E.coli expression system.

PRODUCT INFORMATION

Item No.: PPBD-146
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Pegloticase
Brand Name(s): Krystexxa
Classification: Recombinant Enzymes
Amino Acid Sequence: Identical to DB09208

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016 Aug;8(4):145-59.

[2] Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007 Mar;56(3):1021-8.

Contact Us